非小细胞肺癌组织中LncRNA SNHG3、LncRNA SNHG15的表达与患者病理特征、预后的关系*

doi:10.3969/j.issn.1671-7171.2025.02.003

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1307 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨非小细胞肺癌(NSCLC)组织中长链非编码RNA(LncRNA)小核仁RNA宿主基因3(SNHG3)、LncRNA SNHG15的表达与患者病理特征、预后的关系。【方法】回顾性分析2017年1月至2021年9月在本院行肺癌根治术的179例NSCLC患者的临床资料,术后随访3年,记录患者无病生存情况。采用实时荧光定量PCR检测患者癌组织、癌旁组织中LncRNA SNHG3、LncRNA SNHG15表达情况并比较,分析NSCLC患者癌组织中LncRNA SNHG3、LncRNA SNHG15表达与患者病理特征、预后的关系。【结果】癌组织中LncRNA SNHG3、LncRNA SNHG15相对表达量均高于癌旁组织(P<0.05)。Cox回归分析显示:病理分期、分化程度及LncRNA SNHG3、LncRNA SNHG15表达是NSCLC患者预后的影响因素(P<0.05)。受试者工作特征(ROC)曲线分析结果显示:LncRNA SNHG3、LncRNA SNHG15相对表达量二者联合预测NSCLC患者预后的灵敏度、特异度、ROC曲线下面积(AUC)均高于两者单独预测。LncRNA SNHG3、LncRNA SNHG15低表达患者的生存曲线均优于高表达患者(P<0.05)。【结论】NSCLC患者癌组织中LncRNA SNHG3、LncRNA SNHG15表达与病理特征及预后有关,二者联合预测NSCLC患者的预后效能良好,LncRNA SNHG3、LncRNA SNHG15低表达者治疗后复发、转移风险更低。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	秦爱英
	熊向乐

关键词 ：癌, 非小细胞肺, RNA, 长链非编码, 预后

Abstract：【Objective】To investigate the relationship of the expression of long non-coding RNA (LncRNA) small nucleolar RNA host gene 3 (SNHG3) and LncRNA SNHG15 in non-small cell lung cancer (NSCLC) tissues with the pathological characteristics and prognosis of patients.【Methods】The clinical data of 179 patients with NSCLC who underwent radical resection for lung cancer in our hospital from January 2017 to September 2021 were retrospectively analyzed, and the disease-free survival of the patients was recorded after 3 years of postoperative follow-up. Real-time fluorescent quantitative PCR was used to detect and compare the expression of LncRNA SNHG3 and LncRNA SNHG15 in cancer tissues and adjacent tissues of patients, and analyze the relationship of the expression of LncRNA SNHG3 and LncRNA SNHG15 in cancer tissues with the pathological characteristics and prognosis of patients with NSCLC.【Results】The relative expression levels of LncRNA SNHG3 and LncRNA SNHG15 in cancer tissues were higher than those in cancer adjacent tissues (P<0.05). Cox regression analysis showed that pathological stage, differentiation degree, and levels of LncRNA SNHG3 and LncRNA SNHG15 expression were prognostic factors of NSCLC patients (P<0.05). The results of receiver operating characteristic (ROC) curve analysis showed that the sensitivity, specificity and area under ROC curve (AUC) of the combined relative expression level for both LncRNA SNHG3 and LncRNA SNHG15 in predicting the prognosis of NSCLC patients were higher than those predicted by LncRNA SNHG3 and LncRNA SNHG15 alone. The survival curves of LncRNA SNHG3 and LncRNA SNHG15 patients with low expression were better than those with high expression (P<0.05).【Conclusion】The expression of LncRNA SNHG3 and LncRNA SNHG15 in cancer tissues of patients with NSCLC is related to pathological characteristics and prognosis. The combination of both LncRNA SNHG3 and LncRNA SNHG15 is more effective in predicting prognosis of patients with NSCLC.Those with low expression of LncRNA SNHG3 and LncRNA SNHG15 have lower risk of recurrence and metastasis after treatment.

Key words： Carcinoma, Non-Small-Cell Lung RNA, Long Noncoding Prognosis

收稿日期: 2024-11-22

中图分类号:

R734.2

基金资助:*中关村精准医学基金科研项目(ZLXGBXKYXM-035-01)

通讯作者: **E-mail:qayhxw@126.com

引用本文:

秦爱英, 熊向乐. 非小细胞肺癌组织中LncRNA SNHG3、LncRNA SNHG15的表达与患者病理特征、预后的关系^*[J]. 医学临床研究, 2025, 42(2): 184-188.
QIN Aiying, XIONG Xiangle. Expression of LncRNA SNHG3 and LncRNA SNHG15 in Non-Small Cell Lung Cancer Tissues and Relationship with Pathological Features and Prognosis. JOURNAL OF CLINICAL RESEARCH, 2025, 42(2): 184-188.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2025.02.003 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2025/V42/I2/184

[1] 谢娟英,张凯云. SOSNet:一种非对称编码器-解码器结构的非小细胞肺癌CT图像分割模型[J].电子学报,2024,52(3):824.
[2] 朱志朋,虞淦军,许炜. 地舒单抗联合免疫检查点抑制剂在非小细胞肺癌骨转移中的临床研究进展[J].中国肿瘤生物治疗杂志,2024,31(5):528-534.
[3] 夏宁,周泽军,方申存,等. 血清FGL1、LncSChLAP1对晚期非小细胞肺癌免疫治疗效果及预后评估的价值[J].疑难病杂志,2024,23(3):346-351.
[4] 马文波,周俊良,徐晖. 非小细胞肺癌预后相关LncRNAs筛选以及LncRNA AC099850.3对癌细胞增殖、迁移和侵袭的影响[J].现代肿瘤医学,2024,32(4):610-617.
[5] 钱倩雯, 钱文霞. LncRNA SNHG3在非小细胞肺癌中的表达及其临床意义[J].现代医学, 2022, 50(4):408-412.
[6] 中华医学会, 中华医学会肿瘤学分会,中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2018版)[J].中华肿瘤杂志, 2018, 40(12):935-964.
[7] 张凤梅. 培美曲塞维持化疗联合PD-1/PD-L1抑制剂对晚期非小细胞肺癌的临床疗效分析[J].中国现代药物应用,2024,18(12):11-14.
[8] 阮炼杰. LncRNA HOTAIR通过靶向miR-1促进非小细胞肺癌细胞增殖、迁移和侵袭的机制研究[J].现代肿瘤医学,2024(15):2716-2722.
[9] 陈娟,郭金莲,周慧会,等. 长链非编码RNASUCLG2-AS1通过调节微小RNA-491-5p对非小细胞肺癌细胞增殖和免疫逃逸的影响[J].陕西医学杂志,2024,53(7):884-889.
[10] 王钺,李晓冬,王睿,等. CT增强扫描结合外显体LncRNA RP5-977B1对于非小细胞肺癌诊断和预后的价值研究[J].中国CT和MRI杂志,2024,22(6):65-67.
[11] ZHAO L J, SONG X, GUO Y S, et al. Long non-coding RNA SNHG3 promotes the development of non-small cell lung cancer via the miR-1343-3p/NFIX pathway[J].Int J Mol Med,2021, 48(2):147-150.
[12] 王韵,宋姗,彭斐,等. LncRNA SNHG15通过miR-483-3p/DDIT4轴调节非小细胞肺癌细胞的顺铂敏感性和上皮间质转化[J].实用医学杂志,2023,39(5):557-563.
[13] SHUAI Y, MA Z H, LU J W, et al. LncRNA SNHG15: A new budding star in human cancers[J].Cell Prolif,2020,53(1):e12716.
[14] ZHANG J S, RAO D, MA H B, et al. LncRNA SNHG15 contributes to doxorubicin resistance of osteosarcoma cells through targeting the miR-381-3p/GFRA1 axis[J].Open Life Sci,2020,15(1):871-883.
[15] 冀叶, 袁小笋, 张蕾, 等. LncRNA SNHG15在胃癌组织中的表达及临床意义[J].检验医学, 2022, 37(5):409-412.